Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Sold half on the pop was holding this for years. Let the rest ride house money that's how I do dis.
$GERN
Bought on a whim at the open just sold.
Profits going back to core positions.
$JSPR
Picked up a few heavy racks of shares under 2.95 today.
$GLYC
Added some today at 8.05-8.10
$VKTX
I'm going to keep my entire position and double my stash next week.
Made a fortune in the space and I think gains will continue to increase next 12-24 months.
$VKTX
PLX Why now after 15 years of a dual listing?
Simplifying for buyout?
Making calculation of a multiple simpler?
Making milestone payments easier to reflect as cash per share?
No significance just coincidence that this move occurs just ahead of EMA and FDA decision dates?
Simplifying accounting for buyout!
$PLX
$TKD
$SNY
$PFE
Chiesi’s marketing team PLX partner on 102 has a lot to work with when compared to Fabrazyme. Read about it. Less antibodies. Less pain. Less dosing. Probably less decline in renal function. Perhaps the greatest advantage may be subjective wellness of Fabry patients who simply feel better on PLX 102 perhaps due to a longer half-life. Fabry doctors will suggest a change from Fabrazyme to PLX 102 in many patients IMO based on these differences.
Cost may also cause governments and insurance companies to change. 1X/month dosing is an obvious cost-saving for drug and ancillary infusion services. The production cost of the Procellex platform is also significantly less than mammalian cells and thus saving may be able to be passed on.
Chiesi is already working on its marketing plan. They claim to be a Fabry company based solely on their PLX partnership. They have spent significant cash and resources already. I’m assuming they know what they’re doing. Milestones and royalties coming.
PLX
$500 will be here soon enough!
$MDGL
No one loved it under $3.00
always early!
$VKTX
PLX sitting on the standard of care (will become) in a current $2.1 billion Fabry ERT market - growing to nearly $3 billion by end of decade… and sport a $65 million market cap. Ridiculously undervalued is an understatement. Companies Platform is validated with FDA approved drug with Pfizer for Gaucher. 2023 Approvals in Europe & the US are expected to pass with flying colors Q1 & Q2 2023. Chiesi PLX partner on 102 Fabry has negotiated 15-35% royalties is Europe & 15-40% royalties in the USA with 1.1 Billion in milestones that kick in on Approvals. 3 Phase 3 Completed.
Happy New Year!
$PLX
Sanofi or Takeda might throw a curve ball and steal PLX from Chiesi before the approval dates CHMP EU in a few weeks.
Lots of M & A happens as early as Phase 2 PLX has three Phase 3 Trials completed + more data following up on those patients.
The key is on the switch over trial there was over 97%+ retention from patients who switched from Fabrazyme to PLX 102 wanted to stay on PLX drug less side effects and half the infusion times a month is a key factor. SNY might want to monopolize the Fabry space. Takeda can also come in and swoop 102 from Chiesi time will tell.
$PLX
$SNY
$TAK
"The efficacy is there.. facts! Just as effective as Fabrazyme and more effective than Replagal (I believe will show LT superiority to Fabrazyme in efficacy as well)
Fewer premeds needed
Fewer reactions
Fewer AEs
Fewer ADAs
Potentially 50%+ fewer infusions
No risk of contamination and drug shortages, unlike FAB and REP
97% retention rate on switch over trials patients wanted to stay on PLX 102 three phase trials 3 completed The Fabry community is relatively small and well connected. Don’t think for a minute that they don’t understand these benefits and hear these testimonials. Most are eagerly awaiting its approval" Also the platfrom has been validated as Pfizer partnered with them for FDA approved drug for gaucher.
$PLX
$SNY
$PFE
$TAK
Some people see the angles before they are being played others don't simple as that up over 300% here.
$ALT
Selling half my shares at $12.50 then let the other half run the houses money.
Adding end of Feb options.
$VKTX
$PLX Takeda (Replagal) was never able to enter the US market. It would be interesting to see if they make a play for (Unigal PLX 102) Would take about $350m (includes $150m exit fee) to erase Chiesi from the picture. What’s another $2b for them to buy the WW rights to Unigal and have a direct, potentially superior Fabry ERT that can compete globally with Fabrazyme in a $3.Billion annual market by 2030. Protalix could sell the rights outright, collect $2B cash, and then manufacture Unigal for Takeda as additional revenue source.
At a minimum, maybe this potential scenario causes Chiesi to consider an acquisition they may not normally consider? Free markets cause interesting moves. At the end of the day, it’s mainly about the money and ROI.
The delisting from TASE and focusing on a single listing the NYSE American is a signal of a buyout or Merger is in the works.
$PLX
$TAK
$SNY
Riding free shares 300% profits last week was holding for 6 months worth the wait being patient & nailed some of the Jan 2023 calls a few weeks ago. It's going to go higher! 300 Million in financing to complete remaining trails Nash market is worth tens of Billions of dollars should be years ahead of the rest. Look for Buyout in 2023.
$MDGL
Sold last week .85 to 8.75-$9.00 in less than 4 months.
$CABA
PLX 102 for Fabry disease Chmp in January 2023 (350 Million milestone payment on EU approval & 650 Million on US approval Quarter 2 2023 + 15-35% royalties in Europe & up to 40% royalty in US looking to capture new standard of care for Fabry 2.1 Billion market. over 95% retention rate from PLX 102 on switch over trials Patients wanted to stay on PLX 102. Three Phase 3 completed. Partner is Chiesi 3 Billion revenue generating company with 6000 employees Chiesi has over well over 200 Million invested in 102 for Fabry with PLX look for a possible buyout. I believe Takeda or Sanofi could make a bid also possibly Pfizer might be in the mix partnered with PLX with FDA approved drug for Gaucher disease. validating the platform Chiesi & PLX look to make 150-200 Million each in year 1 capturing 25% of the market & growing each additional year. Positive EPS scheduled in 2023 Happy Holidays!
KOL Pegunigalsidase alfa (PRX-102) for Fabry Disease KOL Event December 2022
https://protalixbiotherapeutics.gcs-web.com/static-files/eaedf07b-6f15-4c61-9e4d-0cd3465b583b
$PLX
PLX has potential to see significant gains in the coming weeks and months. Milestone payments due on approvals =over $14.50 a share
1. 60 Million market cap today. $1.19 per share
2. 1.1 Billion due on milestone payments for approvals in Europe in the US from Chiesi Italian conglomerate with 3 Billion in revenue and 6000 employees. Also PLX will receive between 15-40% on top of those milestone payments.
3. PLX 102 for Fabry will most likely be the new standard in care in Fabry a 2.2 Billion dollar market
4. Over 95% retention rate from trials who switched over to 102 they wanted to stay on PLX 102 for Fabry (less side effects & once a month infusion instead of 2 infusions.
5. This stock was trading in the 6-7 dollar range before a CRL was issued for inspection due to Covid 19 restrictions.
PLX & Chiesi look to capture 25% first year stating in 2023 equaling 150-200 Million in revenue for each company.
6. PLX 102 I believe will take over 50% of the Fabry market with in 2 years and more than 50% in year 3
7. I believe Chiesi will buy PLX they have 220 Million invested in PLX 102 so far and have Billions owed in the coming years.
8. I believe there are other companies interested in buying PLX including Takeda, Sanofi & possibly Pfizer who is already partnered with them for an FDA approved drug for Gaucher. I believe Chiesi will end up with PLX.
9. CHMP schedule in a few weeks from now in January 2023 (350 Million Milestone payment due on European approval)
10. PDUFA scheduled early Q2 2023 over 650 Million on US approval in milestone payments due.
11. PLX will be cash flow positive with 150-200 Million in revenue coming in for PLX 102 starting in 2023.
12. Pegunigalsidase alfa (PRX-102) for Fabry DiseaseKOL Event December 2022 https://protalixbiotherapeutics.gcs-web.com/static-files/eaedf07b-6f15-4c61-9e4d-0cd3465b583b
$PLX
good morning duck dung quantum leap orbit launch bean stalk mover
Weeeeeeeeeeeee
$NERV
Weeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeee
https://tenor.com/view/airtime-weeee-jump-truck-tricks-gif-17480246
$NERV
Weeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeee
$NERV
Like I said shes in launch into orbit mode technical analysis 101
Weeeeeeeeeeeeeeeeeeeeeeee dance 2.0
20's are coming
$NERV
Looks like a coiled spring ready to do the ding dong quantum leap. Jack Rabbit leap frog.
5 million float possible approval for unmet medical need.
$NERV
What is your price prediction near term? Sextuplets and Richard Simmons party time bought at 8.63 today
Weeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeee
$NERV
where is the wave 4 going intowave 5 guy wow man write this guy a ticket.
$NERV
Wave 5 that was funny man really that was a good one dumpty time.
Needs to retest the 6's junior
$NERV
I don't even pay attention to these low level stocks Amateur hour time.
what ever you don't know charts go off an run away son.
Going to the low 6's technical analysis 101
$NERV
technical analysis on a quarter penny lol lmao
OK lol lmao
$NERV
Timber RSI 72 learn technical analysis son.
$NERV
hehehehe LMAO wave 4-5 NO WRONG! humpty dumpty time.
$NERV
Bleeding cash they did a reverse split a few months ago look for offerings bloat the float and then do another reverse split that's how the game works son.
$NERV
Ichimoku Base Line nuff said
Nah this thing is toast. Meme stock joke. Chart says its going back down to the 6's at least.
$NERV
Wave 4 is finished 17 people in the study. This thing is about to tank. RSI way out of wack.
-- Interim Phase 1/2 results for zilovertamab plus ibrutinib in MCL presented at ASCO 2022, with ORR of 85% compare favorably to historical single agent ibrutinib data and support moving into Phase 3 Study ZILO-301
-- Interim data from p53-mutated CLL patients in the same Phase 1/2 study showed encouraging activity in sub-group analyses, with landmark PFS of 100% at 36 months, compares favorably to historical PFS for ibrutinib monotherapy
-- Established a clinical trial and supply agreement with Pharmacyclics for the donation of ibrutinib for our global registrational Phase 3 study, ZILO-301, of zilovertamab in patients with MCL, which is on track to be initiated in September 2022
-- Advanced development of ONCT-808, the lead candidate for our autologous CAR-T program targeting ROR1-expressing malignancies, with IND submission on track for later this month
-- Executing IND enabling studies for ONCT-534, the lead candidate in our novel dual-action androgen receptor inhibitor (DAARI) program
-- Extended cash runway guidance to fund operations into the first half of 2024 with $78.9 million in cash and cash equivalents and no debt as of June 30, 2022
ONCT pipeline is showing more promising data than VelsoBio & NBE Therapeutics here is the key & the valuation of where ONCT should be. Abbive wants this pipeline & will make a take over offer sooner than later. The team at ONCT is top notch sesoned vets from some of the top biotech companies in the world. Their Pedigree is next level.
If you take a formula of three buyouts in the last year and change 2.8 Billion Merck on Velsobio & Boehringer Buyout of NBE-Therapeutics for 1.5 Billion & Trillium 2.2 Billion bought by Pfizer Onct is worth north of Billion. Their pipeline is more mature and their top line data is superior. Onct market cap of 67 Million has 20 to 30x ROI potential from these levels.
Merck inks $2.8B VelosBio buyout to snag anti-ROR1 ADC
https://www.fiercebiotech.com › biotech › merck-inks-...
Merck has struck a deal to buy VelosBio for $2.75 billion. The takeover will give Merck control of an antibody-drug conjugate (ADC) that caused objective ...
You've visited this page 5 times. Last visit: 8/21/22
Boehringer inks $1.5B NBE buyout, joining Merck in new ...
https://www.fiercebiotech.com › biotech › boehringer-i...
Boehringer Ingelheim has struck a deal to buy NBE-Therapeutics for €1.2 billion ($1.5 billion) to add a ROR1-directed antibody-drug conjugate
Oncternal therapeutics: Zilovertamab Phase 3 study Ror1 ZILO-301 Kills cancer stem cells. HUGE Improvement Partnered with AbbV better approach then trillium which was bought out by Pfizer for 2.2 Billion for Hematological malignancies cancers. Next we had the 2 ROR1 buyouts last year and half. This stock is about to quantum leap. Under the radar hidden gem. Billion dollar plus market cap in the making. Onct is helping Imbruvica (PCYC) which as bought out by ABBV 21 Billion and has 9 Billion plus in sales. Zilovertamab in combo with Imbruvica is 50% more affective then Imbruvica alone with less side effects. Plus 9 indications in the ONCT pipeline including Prostate & Breast cancer Her2 (39 Billion market for Her2 Breast cancer in 2025 Onct market cap at 65 Million is extremely undervalued. The chart is turning around. Ror1 first in class in the making.
https://www.fiercebiotech.com/biotech/merck-inks-2-8b-velosbio-buyout-to-snag-anti-ror1-adc
This is the most undervalued asset, 'explosive' move coming.
64k on the bid.
Lots of catalysts & hammers about to drop this company is extremely undervalued.
$ONCT